Ovarian cancer vaccine - Antigen Express

Drug Profile

Ovarian cancer vaccine - Antigen Express

Alternative Names: AE-O vaccine; Her-2/neu combo vaccine

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antigen Express
  • Class Cancer vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer

Most Recent Events

  • 26 Apr 2016 Phase I development is ongoing in USA
  • 07 Aug 2008 Phase-I clinical trials in Ovarian cancer (combination therapy) in USA (Parenteral)
  • 09 Jul 2008 Antigen Express files an IND application with the FDA in the US for combination therapy in breast cancer and ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top